DUBLIN, Sept. 20, 2021 /PRNewswire/ -- Gain comprehensive access to over 1400 drug delivery deal records from this report "Global Drug Delivery Partnering Terms and Agreements 2014-2021" that has been added to ResearchAndMarkets.com's offering.
The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.
The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1400 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Drug Delivery deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2014. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.
Key benefits
Global Drug Delivery Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:
- In-depth understanding of Drug Delivery deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
- Identify most active Drug Delivery dealmakers since 2014
- Insight into terms included in a Drug Delivery partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report Scope
Global Drug Delivery Partnering Terms and Agreements 2014-2021 is intended to provide the reader with an in-depth understanding and access to Drug Delivery trends and structure of deals entered into by leading companies worldwide.
Drug Delivery Partnering Terms and Agreements includes:
- Trends in Drug Delivery dealmaking in the biopharma industry since 2014
- Analysis of Drug Delivery deal structure
- Access to headline, upfront, milestone and royalty data
- Access to Drug Delivery contract documents
- Leading Drug Delivery deals by value since 2014
- Most active Drug Delivery dealmakers since 2014
In Global Drug Delivery Partnering Terms and Agreements 2014-2021, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 1400 Drug Delivery deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Drug Delivery dealmaking
2.1. Introduction
2.2. Drug Delivery partnering over the years
2.3. Most active Drug Delivery dealmakers
2.4. Drug Delivery partnering by deal type
2.5. Drug Delivery partnering by therapy area
2.6. Deal terms for Drug Delivery partnering
2.6.1 Drug Delivery partnering headline values
2.6.2 Drug Delivery deal upfront payments
2.6.3 Drug Delivery deal milestone payments
2.6.4 Drug Delivery royalty rates
Chapter 3 - Leading Drug Delivery deals
3.1. Introduction
3.2. Top Drug Delivery deals by value
Chapter 4 - Most active Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Drug Delivery dealmakers
4.3. Most active Drug Delivery partnering company profiles
Chapter 5 - Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Drug Delivery contracts dealmaking directory
Chapter 6 - Drug Delivery dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Companies Mentioned
- 3DMed
- 3M Drug Delivery Systems
- 3P Biopharmaceuticals
- 3PrimeDx
- 3SBio
- A*STAR Agency for Science
- Technology and Research
- A1 Group
- AADi
- Abbott Laboratories
- Abbvie
- Abiogen Pharma
- Absorption Systems
- Accelis Pharma
- Accord Healthcare
- Acella Pharmaceuticals
- Acelrx Pharmaceuticals
- Acerus
- Aceto Corporation
- Ache
- Aclaris Therapeutics
- Acorda Therapeutics
- Actavis (acquired by Watson)
- Actavis (name changed to Allergan)
- Actelion
- Acuity Pharmaceuticals
- Acura Pharmaceuticals
- AdAlta
- Adama
- Adamas Pharmaceuticals
- Adamis Pharmaceuticals
- Adaptive Health
- Adapt Pharma
- Adare Pharmaceuticals
- Adhesys Medical
- Adhezion Biomedical
- Advanced Catheter Therapies
- Advanced Cooling Therapy
- Advanced Dosage Forms
- Advanced Medical Solutions
- Advaxis
- Adverum Biotechnologies
- Aegis Therapeutics
- Aequus Pharmaceuticals
- Aerie Pharmaceuticals
- Aerogen
- Aero Pump
- AEterna Zentaris
- Afaxys Pharmaceuticals
- AFT Pharmaceuticals
- Agalimmune
- Aires Pharmaceuticals
- AIT Therapeutics
- Ajad Medical
- Akorn
- Akrivis Technologies
- Albany Molecular Research
- Albion
- Albumedix
- Alcyone Lifesciences
- Alexion Pharmaceuticals
- Alexza Pharmaceuticals
- Alfa Wassermann
- Aligo
- Alimera Sciences
- ALK-Abello
- Allergan
- Alliance for Lupus Research
- AllianceRx Walgreens Prime
- Allogene Therapeutics
- AlloSource
- Almirall
- Alnylam Pharmaceuticals
- Alphamab
- ALRISE Biosystems
- ALS Association
- Altum Pharmaceuticals
- Altus Formulation
- Aluna
- Alvit LCS Pharma
- Alvogen
- Alzyn
- Amarantus BioSciences
- Amedica
- American CryoStem
- American Diabetes Association
- Amerigen Pharmaceuticals
- Amerinet
- AmerisourceBergen
- Amgen
- AMI
- AMPEL BioSolutions
- Anacor Pharmaceuticals
- Andor Pharmaceuticals
- Angelini Pharma
- AnGes MG
- Anika Therapeutics
- ANI Pharmaceuticals
- Anji Pharma
- Antares Pharma
- Anteis
- AntiOp
- Apellis Pharmaceuticals
- Aphria
- AppianRx
- Applied DNA Sciences
- APR Applied Pharma Research
- Aprecia Pharmaceuticals
- Apricus Biosciences
- Apsen Farmacutica
- Aptar Pharma
- Aquestive Therapeutics
- Aralez Pharmaceuticals
- Arbutus
- Arcoral Pharma
- Arcturus Therapeutics
- Arecor
- Argentum Pharmaceuticals
- argenx
- Aries Pharmaceuticals
- Arisaph Pharmaceuticals
- Armas Pharmaceuticals
- Arsia Therapeutics
- Artes Biotechnology
- Art of Technology
- Asahi Kasei
- Asahi Kasei Kuraray Medica
- Ascendia Pharmaceuticals
- Ascend Therapeutics
- Ascensia Diabetes Care
- Asieris MediTech
- Asklepios Biopharmaceutical
- Aspen Global
- Aspen Pharmacare Canada
- Astellas Pharma
- Astellas Pharma Europe
- AstraZeneca
- Athenex
- Atlangram
- Aucta Pharmaceuticals
- Audentes Therapeutics
- Aura Biosciences
- Auris Medical
- Aurora Cannabis
- Auspherix
- Austrianova Singapore
- Autotelic
- Auxilium Pharmaceuticals
- Auxly Cannabis Group
- Avacta
- Avalanche Biotechnologies
- Avanos Medical
- Avara Pharmaceutical Services
- AV Cannabis
- Avenue Therapeutics
- Avidity NanoMedicines
- Avion Pharmaceuticals
- Avior Bio
- Aviragen Therapeutics
- Avita Medical
- AXIM Biotechnologies
- Aytu BioScience
- Azaya Therapeutics
- BASF
- Bausch & Lomb
- Baxter International
- Bayer
- Bayer Healthcare
- Bazelet
- B Braun
- BDD Pharma
- Becton Dickinson
- Bedford Laboratories
- Beijing Double-Crane Pharmaceutical
- Bellerophon Therapeutics
- Bellicum Pharmaceuticals
- Ben-Gurion University
- Ben Venue Laboratories
- Berlin-Brandenburg Center for Regenerative Therapies
- Berlin Chemie
- Besins Healthcare
- Bespak
- Best Choice
- Betaliq
- Bigfoot Biomedical
- Bill and Melinda Gates Foundation
- BIND Therapeutics
- BioArctic Neuroscience
- biOasis Technologies
- BioCardia
- BIOCORP
- Biodel
- BioDelivery Sciences
- Bio DG
- Biogen
- Biohaven Pharmaceutical Holding
- Bioject Medical Technologies
- BiolineRX
- BioLingus
- Biological E
- Biologix FZCo
- Biomedical Advanced Research and Development Authority
- BioNTech
- Biophage Pharma
- BioPharm Group International
- BiopharmX
- BioQ Pharma
- Biosensors International
- Bioventus
- Birdie Biopharmaceuticals
- BLP Management
- BMG Pharmaceuticals
- Boehringer Ingelheim
- Bora Pharmaceuticals
- Boston Topicals
- Bpifrance
- Braeburn Pharmaceuticals
- Breathe ECig
- Breckenbridge Pharmaceutical
- Breckenridge Pharmaceuticals
- BridgeBio Pharma
- Bridge Medicines
- BrightFocus Foundation
- Brill Pharma
- Bristol-Myers Squibb
- Broda Technologies
- C-Tri
- Cadila Pharmaceuticals
- Calidi Biotherapeutics
- California Institute for Biomedical Research
- Camargo Pharmaceutical Services
- Camarus
- Cam Med
- Camurus
- Cancer Prevention and Research Institute of Texas
- Candela
- Canigma
- Cannabics Pharmaceuticals
- Cannabis Science
- CannaKids
- CannaRoyalty
- CannaSkin
- CanniMed Therapeutics
- CannRx Technology
- CannScience Innovations
- Canntab Therapeutics
- Canopy Growth
- Cantabria Pharma
- Capcium
- Capillary Biomedical
- Capnia
- Capricor Therapeutics
- Caprion Proteomics
- Cara Therapeutics
- Cardinal Health
- Cardiome Pharma
- Cardiovascular Systems
- Caris Life Sciences
- Carisma Therapeutics
- Carlina Technologies
- Carpal Aid
- CarThera
- CASI Pharmaceuticals
- Catalent Pharma Solutions
- Cataract & Laser Institute
- CBDerma Technology
- CBx Data Labs
- CEA-Leti
- Ceapro
- Cedars-Sinai Medical Center
- Celdara Medical
- Celgene
- Cell Care Therapeutics
- Cellectar Biosciences
- Celling Biosciences
- CellProThera
- Celon Pharma
- Cel Sci
- Central Admixture Pharmacy Services
- Centro de Investigacion Biomedica en Red de Salud Mental
- Cequr
- Cerebral Therapeutics
- Cerenis Therapeutics
- Cerner
- Charite-Universitatsmedizin
- Chemesis
- ChemWerth
- Cheplapharm Arzneimittel
- Chiesi Farmaceutici
- Children's Hospital of Philadelphia
- Children's National Medical Center
- Chimerix
- China Medical System
- China Resources Guokang Pharmaceuticals
- Chinese Academy of Science
- Chiome Bioscience
- Chrono Therapeutics
- Cilian
- Cingulate Therapeutics (CTx)
- Cipher Pharmaceuticals
- Cipla
- Circassia
- Clear Guide Medical
- Clearside Biomedical
- Cleveland Diabetes Care
- Cleveland University Hospitals
- Clinigen
- Clinvest
- CME Medical
- CMIC
- Cocoon Biotech
- Codan Triplus
- Coldstream Laboratories
- Colep
- Collegium Pharmaceuticals
- Colorcon
For more information about this report visit https://www.researchandmarkets.com/r/g2jxyw
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets

Share this article